7 research outputs found
Novel acid-labile and targeted nanoparticles as possible antimalarial drug delivery systems
The multistage life cycle of malaria-causing P. falciparum is complex, making prevention and treatment difficult. As a result of resistance to many antimalarial drugs, novel compounds with unexplored targets are constantly sought after for the purpose of treating the symptoms of malaria. Here, novel compounds were screened for antiplasmodial activity against the symptom-causing asexual intraerythrocytic malaria-causing parasites. Unfortunately, many novel compounds in the drug discovery pipeline and drugs in clinical use possess underlying pharmacological issues that makes administration challenging. These include low aqueous solubility and short half-life which negatively impact bioavailability resulting in toxicity. This, in turn, increases patient non-compliance and the emergence of drug-resistant strains.
Nanoparticles (NP) have the ability to mask drugs from the external environment while increasing circulation time and often alleviate many issues at once. Furthermore, the selected drugs do not need to be modified. Drug conjugation NPs with a targeting ligand and stimuli-responsive linkers have been extensively researched in many diseases, however, none have been reported for malaria clinically. Here, the first acid-labile targeted NP (tNP) that exploits the biology of infected erythrocytes and the specialised food vacuole (FV) of P. falciparum is interrogated for ability to decrease toxicity while retaining antimalarial activity.
This dissertation describes the effect of tNPs on the efficacy and toxicity of selected compounds. In vitro haemolysis and cytotoxicity assays revealed that the tNPs are biocompatible to erythrocytes and HepG2 cells. The data also shows that tNPs decrease the toxicity of drugs and the chosen novel compound against human cells. A decrease in antiplasmodial activity was observed in vitro for the tNPs when compared to the novel compound and drugs on their own. However, this was due to the biogenesis of the FV and a shortened window of release. Nonetheless, the NP backbone was not active against P. falciparum intraerythrocytic parasites whereas tNPs were, showing activity due to released drug. The targeting ligand was also not specific for antiplasmodial activity.
Although a significant loss in activity is observed, the results presented here suggests that these novel acid-labile tNPs serve as an attractive starting point for targeted treatment of malaria with an improved patient tolerance. Furthermore, novel compounds with issues can be selected without having to be modified or completely discarded. Therefore, increasing the chances of finding a variety of compounds that can be used to treat malaria while keeping patients safe.Dissertation (MSc (Biochemistry))--University of Pretoria, 2020.NRFBiochemistryMSc (Biochemistry)Unrestricte
Facile route to targeted, biodegradable polymeric prodrugs for the delivery of combination therapy for malaria
A facile synthetic methodology has been developed to prepare multifaceted polymeric prodrugs that are targeted, biodegradable, and nontoxic, and used for the delivery of combination therapy. This is the first instance of the delivery of the WHO recommended antimalarial combination of lumefantrine (LUM, drug 1) and artemether (AM, drug 2) via a polymeric prodrug. To achieve this, reversible addition-fragmentation chain transfer (RAFT)-mediated polymerization of N-vinylpyrrolidone (NVP) was conducted using a hydroxy-functional RAFT agent, and the resulting polymer was used as the macroinitiator in the ring-opening polymerization (ROP) of α-allylvalerolactone (AVL) to synthesize the biodegradable block copolymer of poly(N-vinylpyrrolidone) and poly(α-allylvalerolactone) (PVP-b-PAVL). The Ï-end thiol group of PVP was protected using 2,2âČ-pyridyldisulfide prior to the ROP, and was conveniently used to bioconjugate a peptidic targeting ligand. To attach LUM, the allyl groups of PVP-b-PAVL underwent oxidation to introduce carboxylic acid groups, which were then esterified with ethylene glycol vinyl ether. Finally, LUM was conjugated to the block copolymer via an acid-labile acetal linkage in a âclickâ-type reaction, and AM was entrapped within the hydrophobic core of the self-assembled aggregates to render biodegradable multidrug-loaded micelles with targeting ability for combination therapy.The South African Research Chairs Initiative of the Department of Science and Technology (DST), the National Research Foundation (NRF) of South Africa, SARCHI: Communities of Practice in Malaria Elimination and SARChI Research Chair UID 84627 and UID 84627.http://pubs.acs.org/journal/abseba2021-10-07hj2021BiochemistryGeneticsMicrobiology and Plant Patholog
Poly(N-vinylpyrrolidone) antimalaria conjugates of membrane-disruptive peptides
The concepts of polymerâpeptide conjugation and self-assembly were applied to antimicrobial peptides (AMPs) in the development of a targeted antimalaria drug delivery construct. This study describes the synthesis of α-acetal, Ï-xanthate heterotelechelic poly(N-vinylpyrrolidone) (PVP) via reversible additionâfragmentation chain transfer (RAFT)-mediated polymerization, followed by postpolymerization deprotection to yield α-aldehyde, Ï-thiol heterotelechelic PVP. A specific targeting peptide, GSRSKGT, for Plasmodium falciparum-infected erythrocytes was used to sparsely decorate the α-chain ends via reductive amination while cyclic decapeptides from the tyrocidine group were conjugated to the Ï-chain end via thiolâene Michael addition. The resultant constructs were self-assembled into micellar nanoaggregates whose sizes and morphologies were determined by dynamic light scattering (DLS) and transmission electron microscopy (TEM). The in vitro activity and selectivity of the conjugates were evaluated against intraerythrocytic P. falciparum parasites.© 2020 American Chemical Societyhttp://pubs.acs.org/journal/bomaf62021-11-06hj2021BiochemistryGeneticsMicrobiology and Plant Patholog
New transmission-selective antimalarial agents through hit-to-lead optimization of 2-([1,1 '-Biphenyl]-4-carboxamido)benzoic acid derivatives
Malaria elimination requires multipronged approaches, including
the application of antimalarial drugs able to block humanto-
mosquito transmission of malaria parasites. The transmissible
gametocytes of Plasmodium falciparum seem to be highly
sensitive towards epidrugs, particularly those targeting demethylation
of histone post-translational marks. Here, we report
exploration of compounds from a chemical library generated
during hit-to-lead optimization of inhibitors of the human
histone lysine demethylase, KDM4B. Derivatives of 2-([1,1â-
biphenyl]-4-carboxamido) benzoic acid, around either the
amide or a sulfonamide linker backbone (2-(arylcarboxamido)
benzoic acid, 2-carboxamide (arylsulfonamido)benzoic
acid and N-(2-(1H-tetrazol-5-yl)phenyl)-arylcarboxamide),
showed potent activity towards late-stage gametocytes (stage
IV/V) of P. falciparum, with the most potent compound reaching
single digit nanomolar activity. Structure-activity relationship
trends were evident and frontrunner compounds also displayed
microsomal stability and favourable solubility profiles. Simplified
synthetic routes support further derivatization of these
compounds for further development of these series as malaria
transmission-blocking agents.South African National Research Foundation;
BMGF Grand Challenges Africa;
South African Medical Research Council (SA MRC);
South Carolina SmartStateÂź Endowed Chair for Drug Discovery.https://chemistry-europe.onlinelibrary.wiley.com/journal/14397633am2023BiochemistryGeneticsMicrobiology and Plant PathologySchool of Health Systems and Public Health (SHSPH)UP Centre for Sustainable Malaria Control (UP CSMC
Antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains inhibit microtubule and hemozoin formation : structureâactivity relationship and in vivo oral efficacy studies
A novel series of antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains at the C2 position, which possess dual asexual blood and sexual stage activities, is presented. Structureâactivity relationship studies revealed that the 1-benzylbenzimidazole analogues possessed submicromolar asexual blood and sexual stage activities in contrast to the 1H-benzimidazole analogues, which were only active against asexual blood stage (ABS) parasites. Further, the former demonstrated microtubule inhibitory activity in ABS parasites but more significantly in stage II/III gametocytes. In addition to being bona fide inhibitors of hemozoin formation, the 1H-benzimidazole analogues also showed inhibitory effects on microtubules. In vivo efficacy studies in Plasmodium berghei-infected mice revealed that the frontrunner compound 41 exhibited high efficacy (98% reduction in parasitemia) when dosed orally at 4 Ă 50 mg/kg. Generally, the compounds were noncytotoxic to mammalian cells.The University of Cape Town, South African Medical Research Council and South African Research Chairs Initiative of the Department of Science and Innovation, administered through the South African National Research Foundation (NRF) and a NRF Community of Practice on âEvaluating Malaria Control Interventionsâ.http://pubs.acs.org/loi/jmcmar2022-04-12hj2021BiochemistryGeneticsMicrobiology and Plant PathologyUP Centre for Sustainable Malaria Control (UP CSMC
Exploring the transmission-blocking activity of antiplasmodial 3,6-diarylated imidazopyridazines
The effectiveness of current antimalarial therapies that cure patients of the pathogenic asexual blood stages is rapidly declining due to the spread of antimalarial drug resistance. This requires the development of novel chemotypes curative for asexual blood stages but additionally, such chemotypes should also target the sexually differentiated gametocytes and thereby block disease transmission. Kinase inhibitors, specifically imidazopyridazines, were previously described as highly effective, dual-active compounds in vitro. However, amongst other shortcomings, poor solubility and cardiotoxicity risks prevented these compounds from being further developed. In a recent study, novel 3,6-diarylated imidazopyridazine derivatives showed improved solubility and a decrease in inhibition of the human ether-a-go-go-related gene (hERG), suggesting reduced cardiotoxicity risks, with potent sub-micromolar antiplasmodial activities. Here, we report the in vitro activity of these 3,6-diarylated imidazopyridazine derivates against both asexual blood and gametocyte stages of the human malaria parasite, Plasmodium falciparum, in vitro. We highlight several potentially dual-active compounds with nanomolar activities (IC50âs 0.7â104â
nM) against both drug sensitive and resistant strains of P. falciparum with these compounds also displaying activity against transmissible gametocytes (IC50âs 1180.3â1787.5â
nM). Taken together, the new generation 3,6-diarylated imidazopyridazines have potent activity against P. falciparum parasites in vitro with improved physicochemical and toxicity profiles.The South African Medical Research Council, the DST/NRF South African Research Chairs Initiative Grants and a Communities of Practice grant.https://www.tandfonline.com/loi/ttrs202022-10-20hj2022BiochemistryGeneticsMicrobiology and Plant PathologyUP Centre for Sustainable Malaria Control (UP CSMC
Benzimidazole derivatives are potent against multiple life cycle stages of Plasmodium falciparum malaria parasites
The continued emergence of resistance to front-line antimalarial treatments is of great concern. Therefore, new compounds that potentially have a novel target in various developmental stages of Plasmodium parasites are needed to treat patients and halt the spread of malaria. Here, several benzimidazole derivatives were screened for activity against the symptom-causing intraerythrocytic asexual blood stages and the transmissible gametocyte stages of P. falciparum. Submicromolar activity was obtained for 54 compounds against asexual blood stage parasites with 6 potent at IC50 < 100 nM while not displaying any marked toxicity against mammalian cells. Nanomolar potency was also observed against gametocytes with two compounds active against early stage gametocytes and two compounds active against late-stage gametocytes. The transmission-blocking potential of the latter was confirmed as they could prevent male gamete exflagellation and the lead compound reduced transmission by 72% in an in vivo mosquito feeding model. These compounds therefore have activity against multiple stages of Plasmodium parasites with potential for differential targets.Supporting Information 1 : Figure S1: screening cascade; chemical and spectroscopic information on new compounds (PDF)Supporting Information 2 : Summary of all data for all in vitro experiments (XLSX)https://pubs.acs.org/journal/aidcbchj2021BiochemistryGeneticsMicrobiology and Plant PathologyUP Centre for Sustainable Malaria Control (UP CSMC